CN102076661B - 前列腺素d2受体的拮抗剂 - Google Patents
前列腺素d2受体的拮抗剂 Download PDFInfo
- Publication number
- CN102076661B CN102076661B CN200980125478.4A CN200980125478A CN102076661B CN 102076661 B CN102076661 B CN 102076661B CN 200980125478 A CN200980125478 A CN 200980125478A CN 102076661 B CN102076661 B CN 102076661B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- methyl
- phenoxy group
- acetic acid
- methoxyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/42—Y being a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
- C07C321/20—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
- C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
Description
化合物编号 | R2 | R3 | R4 | R6 | x | R11 | M+H |
1 | H | H | OCH3 | 4-氯-苯甲酰氨基 | 0 | CH2CF3 | 540 |
2 | H | H | OCH3 | 2,2-二甲基-丙酰氨基 | 0 | CH2CF3 | 486 |
3 | H | H | OCH3 | 3-苯甲基-脲基 | 0 | CH2CF3 | 535 |
4 | H | H | OCH3 | 4-氯-苯甲酰氨基 | 0 | 4-氯苯基 | 569 |
5 | H | H | OCH3 | 2,2-二甲基-丙酰氨基 | 0 | 4-氯苯基 | 515 |
6 | H | H | OCH3 | 3-苯甲基-脲基 | 0 | 4-氯苯基 | 564 |
7 | H | H | OCH3 | 2,2-二甲基-丙酰氨基 | 0 | 叔丁基 | 460 |
8 | H | H | OCH3 | 4-氯-苯甲酰氨基 | 0 | 叔丁基 | 515 |
9 | H | H | OCH3 | 2,2-二甲基-丙酰氨基 | 0 | 异丙基 | 446 |
化合物编号 | R2 | R3 | R4 | R6 | x | R11 | M+H |
48 | H | Cl | H | 22-二甲基-丙酰氨基 | 2 | 叔丁基 | 496 |
49 | H | H | OCHF2 | 22-二甲基-丙酰氨基 | 0 | CH2CF3 | 522 |
50 | H | H | OCHF2 | 22-二甲基-丙酰氨基 | 2 | CH2CF3 | 554 |
51 | H | H | CH3 | 22-二甲基-丙酰氨基 | 0 | CH2CF3 | 470 |
52 | H | H | Cl | 22-二甲基-丙酰氨基 | 0 | 异丙基 | 450 |
53 | H | H | Cl | 22-二甲基-丙酰氨基 | 0 | CH2CF3 | 490 |
54 | H | CF3 | H | 22-二甲基-丙酰氨基 | 0 | 异丙基 | 484 |
55 | H | H | CH=CH2 | 22-二甲基-丙酰氨基 | 0 | CH2CF3 | 482 |
56 | H | H | CH2CH3 | 22-二甲基-丙酰氨基 | 0 | CH2CF3 | 484 |
57 | H | H | OCH3 | 2-氧代-咪唑烷-1-基 | 0 | CH2CF3 | 471 |
58 | H | H | OCH3 | 4-苯甲酰氨基 | 0 | 叔丁基 | 480 |
59 | H | H | Cl | 2,2-二甲基-丙酰氨基 | 0 | 叔丁基 | 464 |
60 | H | H | Cl | 4-氯-苯甲酰氨基 | 0 | 叔丁基 | 518 |
61 | H | H | Cl | 异丁酰氨基 | 0 | 叔丁基 | 450 |
62 | H | H | OCH3 | 3-氟-苯甲酰氨基 | 0 | 叔丁基 | 498 |
63 | H | H | OCH3 | 4-氟-苯甲酰氨基 | 0 | 叔丁基 | 498 |
64 | H | H | OCH3 | 2-氟-苯甲酰氨基 | 0 | 叔丁基 | 498 |
65 | H | H | OCH3 | 2,4-二氯-苯甲酰氨基 | 0 | 叔丁基 | 549 |
66 | H | H | OCH3 | 3,5-二氯-苯甲酰氨基 | 0 | 叔丁基 | 549 |
67 | H | H | OCH3 | 3,5-二氟-苯甲酰氨基 | 0 | 叔丁基 | 516 |
68 | H | H | OCH3 | 3-三氟甲基-苯甲酰氨基 | 0 | CH2CF3 | 574 |
69 | H | H | OCH3 | 4-三氟甲基-苯甲酰氨基 | 0 | CH2CF3 | 574 |
70 | H | H | OCH3 | (吡啶-3-羰基)-氨基 | 0 | CH2CF3 | 507 |
71 | H | H | OCH3 | (吡啶-4-羰基)-氨基 | 0 | CH2CF3 | 507 |
72 | H | H | OCH3 | 5-二甲氨基-萘-1-磺酰氨基 | 0 | 叔丁基 | 609 |
73 | H | H | OCH3 | 2,2-二甲基-丙酰氨基 | 1 | 叔丁基 | |
74 | H | H | OCH3 | 2,2-二甲基-丙酰氨基 | 2 | 叔丁基 | |
75 | H | H | OH | 2,2-二甲基-丙酰氨基 | 0 | 叔丁基 | |
76 | H | H | OH | 2,2-二甲基-丙酰氨基 | 1 | 叔丁基 |
化合物编号 | hDP2(μM) | hDP1(μM) |
化合物1 | A | C |
化合物2 | A | C |
化合物3 | A | ND |
化合物4 | A | ND |
化合物5 | A | ND |
化合物6 | A | ND |
化合物7 | A | C |
化合物8 | A | ND |
化合物9 | A | ND |
化合物10 | A | ND |
化合物11 | A | ND |
化合物12 | A | ND |
化合物13 | A | ND |
化合物14 | A | ND |
化合物编号 | hDP2(μM) | hDP1(μM) |
化合物15 | A | ND |
化合物16 | A | ND |
化合物17 | A | C |
化合物18 | A | A |
化合物19 | A | C |
化合物20 | A | ND |
化合物21 | A | ND |
化合物22 | A | ND |
化合物23 | A | ND |
化合物24 | A | ND |
化合物25 | A | ND |
化合物26 | A | ND |
化合物27 | A | ND |
化合物28 | A | ND |
化合物29 | A | ND |
化合物30 | A | C |
化合物31 | A | ND |
化合物32 | A | C |
化合物33 | A | ND |
化合物34 | A | ND |
化合物35 | A | ND |
化合物36 | A | ND |
化合物37 | A | ND |
化合物38 | B | ND |
化合物39 | A | ND |
化合物40 | A | ND |
化合物41 | A | ND |
化合物42 | C | ND |
化合物43 | A | ND |
化合物44 | A | ND |
化合物45 | C | ND |
化合物46 | B | ND |
化合物47 | A | ND |
化合物48 | A | ND |
化合物49 | A | ND |
化合物50 | A | ND |
化合物51 | A | ND |
化合物52 | A | ND |
化合物53 | A | ND |
化合物54 | A | ND |
化合物55 | A | ND |
化合物56 | A | ND |
化合物57 | B | C |
化合物编号 | hDP2(μM) | hDP1(μM) |
化合物58 | A | A |
化合物59 | A | A |
化合物60 | A | A |
化合物61 | A | A |
化合物62 | A | A |
化合物63 | A | A |
化合物64 | A | A |
化合物65 | A | A |
化合物66 | A | A |
化合物67 | A | A |
化合物68 | A | A |
化合物69 | A | A |
化合物70 | A | B |
化合物71 | A | B |
化合物72 | B | ND |
化合物73 | A | A |
化合物74 | A | A |
化合物75 | A | A |
化合物76 | A | A |
化合物77 | A | A |
雷马曲班(Ramatroban) | B | C |
Claims (33)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7831108P | 2008-07-03 | 2008-07-03 | |
US61/078,311 | 2008-07-03 | ||
PCT/US2009/049621 WO2010003120A2 (en) | 2008-07-03 | 2009-07-02 | Antagonists of prostaglandin d2 receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102076661A CN102076661A (zh) | 2011-05-25 |
CN102076661B true CN102076661B (zh) | 2014-04-09 |
Family
ID=41008689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980125478.4A Expired - Fee Related CN102076661B (zh) | 2008-07-03 | 2009-07-02 | 前列腺素d2受体的拮抗剂 |
Country Status (19)
Country | Link |
---|---|
US (4) | US8071807B2 (zh) |
EP (1) | EP2307362A4 (zh) |
JP (1) | JP5531370B2 (zh) |
KR (1) | KR101325367B1 (zh) |
CN (1) | CN102076661B (zh) |
AR (1) | AR074165A1 (zh) |
AU (1) | AU2009266793B2 (zh) |
BR (1) | BRPI0913930A2 (zh) |
CA (1) | CA2729292C (zh) |
EA (1) | EA019351B1 (zh) |
GB (1) | GB2461629B (zh) |
HK (1) | HK1156301A1 (zh) |
IL (1) | IL210000A (zh) |
MX (1) | MX2010014172A (zh) |
PE (1) | PE20100094A1 (zh) |
TW (1) | TWI403319B (zh) |
UY (1) | UY31956A (zh) |
WO (2) | WO2010003120A2 (zh) |
ZA (1) | ZA201009090B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US20110098352A1 (en) * | 2008-02-01 | 2011-04-28 | Amira Pharmaceuticals, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
CN101952244B (zh) | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | 前列腺素d2受体的n,n-二取代氨基烷基联苯拮抗剂 |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
US8497381B2 (en) * | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
EP2268611A2 (en) * | 2008-04-02 | 2011-01-05 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
US8071807B2 (en) * | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
US20100173313A1 (en) * | 2009-01-08 | 2010-07-08 | Amira Pharmaceuticals, Inc. | Biomarkers of inflammation |
US8785393B2 (en) | 2009-07-31 | 2014-07-22 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists |
CN102596902A (zh) * | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
CN102812000A (zh) | 2010-01-06 | 2012-12-05 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
US9034888B2 (en) | 2010-02-17 | 2015-05-19 | Universite Laval | Substituted 2-imidazolidones and analogs |
CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
US9820951B2 (en) | 2011-01-14 | 2017-11-21 | National Jewish Health, A Non-Profit Organization | Pulmonary disease treatment and diagnosis based on Arhgef1 |
US8759386B2 (en) * | 2011-01-24 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
CA2829105C (en) | 2011-03-31 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
AU2012356076A1 (en) | 2011-12-21 | 2014-08-14 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
PL2802351T3 (pl) | 2012-01-09 | 2019-11-29 | Adc Therapeutics Sa | Środki do leczenia potrójnie negatywnego raka piersi |
JP6127135B2 (ja) | 2012-07-05 | 2017-05-10 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 1−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンd2受容体調節剤としてのそれらの使用 |
CN110776447A (zh) * | 2012-09-20 | 2020-02-11 | 坦普尔大学 | 取代的烷基二芳基衍生物、制备方法和用途 |
ES2690782T3 (es) | 2012-10-24 | 2018-11-22 | Nyu Winthrop Hospital | Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro |
EP3139943A4 (en) * | 2014-05-06 | 2018-07-18 | Northwestern University | Combinations of nmdar modulating compounds |
CN104016878B (zh) * | 2014-06-24 | 2015-06-10 | 中国药科大学 | 芳基乙酸类衍生物、其制备方法及其医药用途 |
WO2017023912A1 (en) | 2015-08-03 | 2017-02-09 | Temple University - Of The Commonwealth System Of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
CA3053734A1 (en) * | 2017-02-26 | 2018-08-30 | Oat Agrio Co., Ltd. | Thiazole compounds and herbicide |
CN111094988A (zh) | 2017-09-13 | 2020-05-01 | 普罗根尼蒂公司 | 先兆子痫生物标志物及相关系统和方法 |
CN113543852A (zh) | 2019-03-06 | 2021-10-22 | 第一三共株式会社 | 吡咯并吡唑衍生物 |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006005909A1 (en) * | 2004-07-08 | 2006-01-19 | Astrazeneca Ab | Substituted acids for the treatment of respiratory diseases |
CN1767823A (zh) * | 2002-12-20 | 2006-05-03 | 安姆根有限公司 | 哮喘和过敏性炎症调节剂 |
WO2007039736A1 (en) * | 2005-10-06 | 2007-04-12 | Astrazeneca Ab | Novel compounds |
WO2007068894A2 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5239084A (en) * | 1990-06-29 | 1993-08-24 | Hoffmann-La Roche Inc. | Substituted aminoalkyl biphenyl compounds |
US5827868A (en) * | 1991-10-07 | 1998-10-27 | E. R. Squibb & Sons, Inc. | Prostaglandin analogs |
US5565485A (en) * | 1993-03-19 | 1996-10-15 | Merck & Co., Inc. | Biphenyl compounds useful or endothelin antagonists |
US5334598A (en) * | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
US5391566A (en) | 1993-07-20 | 1995-02-21 | Merck & Co., Inc. | Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives |
CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
AU4692399A (en) * | 1998-06-17 | 2000-01-05 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
US6617351B1 (en) * | 1998-07-31 | 2003-09-09 | Eli Lilly And Company | Amide, carbamate, and urea derivatives |
AU782404B2 (en) * | 1999-04-28 | 2005-07-28 | Sanofi-Aventis Deutschland Gmbh | Tri-aryl acid derivatives as PPAR receptor ligands |
DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
CA2383135C (en) * | 1999-08-23 | 2010-11-30 | Hiroyuki Hirai | Method of identifying properties of substance with respect to human prostaglandin d2 receptors |
US20010047027A1 (en) * | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
WO2002094830A2 (en) * | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
US7687664B2 (en) * | 2001-06-04 | 2010-03-30 | Eisai R&D Management Co., Ltd. | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it |
NZ539406A (en) * | 2002-10-30 | 2007-05-31 | Merck Frosst Canada Ltd | Pyridopyrrolizine and pyridoindolizine derivatives |
JP2004182657A (ja) | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Hdlレベル上昇促進剤 |
EP1471057B1 (en) | 2003-04-25 | 2006-01-18 | Actimis Pharmaceuticals, Inc. | Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2 |
EP1675826A1 (en) | 2003-10-14 | 2006-07-05 | Oxagen Limited | Compounds having crth2 antagonist activity |
GB0324763D0 (en) | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
JP4922615B2 (ja) | 2003-11-26 | 2012-04-25 | 武田薬品工業株式会社 | 受容体機能調節剤 |
US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
JP2007186422A (ja) * | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
WO2006018325A1 (en) | 2004-08-17 | 2006-02-23 | Galderma Research & Development, S.N.C. | Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions |
EP1814865A4 (en) * | 2004-09-21 | 2009-09-02 | Wyeth Corp | BENZIMIDAZOL ACETIC ACIDS WITH CRTH2 RECEPTOR ANTAGONISM AND ITS APPLICATIONS |
KR20070089908A (ko) * | 2004-09-21 | 2007-09-04 | 아더시스 인코포레이티드 | Crth2 수용체 길항작용을 나타내는 인돌 아세트산 및이의 용도 |
US20070299122A1 (en) | 2004-11-08 | 2007-12-27 | Tobert Jonathan A | Method of Treating Pathological Blushing |
GB0510584D0 (en) | 2005-05-24 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0518783D0 (en) * | 2005-09-14 | 2005-10-26 | Argenta Discovery Ltd | Indolizine compounds |
JP5114202B2 (ja) | 2005-09-27 | 2013-01-09 | 塩野義製薬株式会社 | Pgd2受容体アンタゴニスト活性を有するスルホンアミド誘導体 |
ES2614090T3 (es) * | 2005-12-29 | 2017-05-29 | Celtaxsys, Inc. | Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa |
KR101397352B1 (ko) | 2006-08-21 | 2014-05-19 | 어레이 바이오파마 인크. | 4-치환된 페녹시페닐아세트산 유도체 |
US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
TWI519508B (zh) | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
CA2691662A1 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | Imidazole derivatives as ccr2 receptor antagonists |
MX2010003621A (es) * | 2007-10-01 | 2010-04-14 | Hoffmann La Roche | N-heterociclil biaril carboxamidas como antagonistas del receptor ccr. |
GB0719521D0 (en) | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
GB0722216D0 (en) | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
GB0722203D0 (en) | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
MX2010007833A (es) * | 2008-01-18 | 2010-08-11 | Oxagen Ltd | Compuestos que tienen actividad antagonista de crth2. |
CN101952244B (zh) * | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | 前列腺素d2受体的n,n-二取代氨基烷基联苯拮抗剂 |
US20110098352A1 (en) * | 2008-02-01 | 2011-04-28 | Amira Pharmaceuticals, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
EP2268611A2 (en) | 2008-04-02 | 2011-01-05 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
US20100173313A1 (en) * | 2009-01-08 | 2010-07-08 | Amira Pharmaceuticals, Inc. | Biomarkers of inflammation |
US8785393B2 (en) | 2009-07-31 | 2014-07-22 | Panmira Pharmaceuticals, Llc | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists |
CN102596193A (zh) | 2009-07-31 | 2012-07-18 | 潘米拉制药公司 | Dp2受体拮抗的皮肤调配物 |
CN102812000A (zh) * | 2010-01-06 | 2012-12-05 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
-
2009
- 2009-07-02 US US12/497,343 patent/US8071807B2/en not_active Expired - Fee Related
- 2009-07-02 KR KR1020117001585A patent/KR101325367B1/ko not_active IP Right Cessation
- 2009-07-02 AU AU2009266793A patent/AU2009266793B2/en not_active Ceased
- 2009-07-02 US US12/999,621 patent/US20110190227A1/en not_active Abandoned
- 2009-07-02 JP JP2011516892A patent/JP5531370B2/ja not_active Expired - Fee Related
- 2009-07-02 UY UY0001031956A patent/UY31956A/es not_active Application Discontinuation
- 2009-07-02 US US12/999,617 patent/US20110144160A1/en not_active Abandoned
- 2009-07-02 CA CA2729292A patent/CA2729292C/en not_active Expired - Fee Related
- 2009-07-02 WO PCT/US2009/049621 patent/WO2010003120A2/en active Application Filing
- 2009-07-02 TW TW098122461A patent/TWI403319B/zh not_active IP Right Cessation
- 2009-07-02 MX MX2010014172A patent/MX2010014172A/es active IP Right Grant
- 2009-07-02 PE PE2009000917A patent/PE20100094A1/es not_active Application Discontinuation
- 2009-07-02 EP EP09774569A patent/EP2307362A4/en not_active Withdrawn
- 2009-07-02 CN CN200980125478.4A patent/CN102076661B/zh not_active Expired - Fee Related
- 2009-07-02 WO PCT/US2009/049631 patent/WO2010003127A2/en active Application Filing
- 2009-07-02 EA EA201100133A patent/EA019351B1/ru not_active IP Right Cessation
- 2009-07-02 BR BRPI0913930A patent/BRPI0913930A2/pt not_active IP Right Cessation
- 2009-07-03 AR ARP090102505A patent/AR074165A1/es not_active Application Discontinuation
- 2009-07-03 GB GB0911563A patent/GB2461629B/en not_active Expired - Fee Related
-
2010
- 2010-12-15 IL IL210000A patent/IL210000A/en not_active IP Right Cessation
- 2010-12-17 ZA ZA2010/09090A patent/ZA201009090B/en unknown
-
2011
- 2011-09-27 US US13/246,688 patent/US8247602B2/en not_active Expired - Fee Related
- 2011-10-10 HK HK11110672.1A patent/HK1156301A1/zh not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1767823A (zh) * | 2002-12-20 | 2006-05-03 | 安姆根有限公司 | 哮喘和过敏性炎症调节剂 |
WO2006005909A1 (en) * | 2004-07-08 | 2006-01-19 | Astrazeneca Ab | Substituted acids for the treatment of respiratory diseases |
WO2007039736A1 (en) * | 2005-10-06 | 2007-04-12 | Astrazeneca Ab | Novel compounds |
WO2007068894A2 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease |
Non-Patent Citations (2)
Title |
---|
《前列腺素拮抗剂在白内障术前的应用观察与分析》;周冬兰等;《广西医学》;20011031;第23卷(第5期);第1204-1205页 * |
周冬兰等.《前列腺素拮抗剂在白内障术前的应用观察与分析》.《广西医学》.2001,第23卷(第5期),第1204-1205页. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102076661B (zh) | 前列腺素d2受体的拮抗剂 | |
CN101952244B (zh) | 前列腺素d2受体的n,n-二取代氨基烷基联苯拮抗剂 | |
US8034826B2 (en) | Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors | |
CN102164894A (zh) | 前列腺素d2受体的杂芳基拮抗剂 | |
TW407144B (en) | Arylalkylamine calcilytic compounds and pharmaceutical compositions containing these compounds | |
ES2788627T3 (es) | Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1H)-ona que tienen actividad tanto antagonista del receptor muscarínico como agonista del receptor adrenérgico beta-2 | |
JP2002527496A (ja) | 化学化合物 | |
JP2011518130A (ja) | プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト | |
CN102245584A (zh) | 溶血磷脂酶受体的拮抗剂 | |
CN103228654A (zh) | 作为JAK抑制剂的咪唑并[1,2-b]哒嗪以及咪唑并[4,5-b]吡啶衍生物 | |
EP2245002A1 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
US20040127533A1 (en) | Sulfonamide derivatives | |
TW202115086A (zh) | Bckdk抑制劑 | |
ES2296774T3 (es) | Compuestos calcioliticos. | |
CN100384420C (zh) | 取代的吡唑在制备用于治疗变应性疾病的药物组合物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1156301 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: PAMELA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: AMIRA PHARMACEUTICALS, INC. Effective date: 20120514 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20120514 Address after: American California Applicant after: Amira Pharmaceuticals Inc. Address before: American California Applicant before: Amira Pharmaceuticals Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1156301 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BRICKELL BIOTECH, INC. Free format text: FORMER OWNER: PAMELA PHARMACEUTICAL CO., LTD. Effective date: 20150506 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150506 Address after: American Florida Patentee after: Brickell biotech Address before: American California Patentee before: Amira Pharmaceuticals Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140409 Termination date: 20180702 |